Sign inJoin waitlistJoin the waitlist

Morana Vojnic

Director, Neuro-Oncology, Rutgers Cancer Institute · Rutgers Health

Credentials: · · · · · · · ·

History

Neuro-Oncology · Rutgers Health
Present
Rutgers Health
Present

Hematology and Medical Oncology
Zucker School of Medicine at Hofstra/Northwell
2019–2022
Internal Medicine
Zucker School of Medicine at Hofstra/Northwell
2016–2019
IEDC Bled School of Management
University of Ljubljana
2008–2012

Research

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers
Cancer Discovery · 2018 · 165 citations
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Cancer Discovery · 2022 · 155 citations
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Case report · Clinical Cancer Research · 2021 · 107 citations

ML
Marc Ladanyi
12 papers
Randy D'Amico
11 papers
Igor Odintsov
8 papers · 6 as a resident
AD
Alexander Drilon
7 papers
Jonathan Sherman
6 papers · 6 as a resident
LD
Lukas Delasos
5 papers · 5 as a resident
Charles Rudin
4 papers
EG
Eric Gladstone
4 papers · 3 as a resident
GW
Gabriella Wernicke
4 papers
Nemanja Novakovic
4 papers · 4 as a resident
Christopher Febres-Aldana
3 papers
GR
Gregory Riely
3 papers

Clinical trials

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Site PI · Not yet recruiting · Phase 2
Nuvation Bio Inc.
2027–2032
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Site PI · Recruiting · Phase 2
Diakonos Oncology Corporation
2025–2032
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Site PI · Recruiting · Phase 3
Nuvation Bio Inc.
2023–2030